BR9908726A - Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto - Google Patents
Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um compostoInfo
- Publication number
- BR9908726A BR9908726A BR9908726-0A BR9908726A BR9908726A BR 9908726 A BR9908726 A BR 9908726A BR 9908726 A BR9908726 A BR 9908726A BR 9908726 A BR9908726 A BR 9908726A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- processes
- diseases
- diabetes
- type
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title abstract 2
- 208000026278 immune system disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 abstract 1
- 108091006442 Mitochondrial phosphate transporters Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 abstract 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrodes Of Semiconductors (AREA)
- Enzymes And Modification Thereof (AREA)
- Bipolar Transistors (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Control Of El Displays (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK34498 | 1998-03-12 | ||
| DK48098 | 1998-04-03 | ||
| DKPA199800938 | 1998-07-15 | ||
| DKPA199801385 | 1998-10-28 | ||
| DKPA199801612 | 1998-12-07 | ||
| PCT/DK1999/000121 WO1999046267A1 (en) | 1998-03-12 | 1999-03-11 | Modulators of protein tyrosine phosphatases (ptpases) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9908726A true BR9908726A (pt) | 2000-11-21 |
Family
ID=27512769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9908726-0A BR9908726A (pt) | 1998-03-12 | 1999-03-11 | Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1080095B1 (enExample) |
| JP (1) | JP2002506072A (enExample) |
| KR (1) | KR20010041814A (enExample) |
| CN (1) | CN1300291A (enExample) |
| AT (1) | ATE308546T1 (enExample) |
| AU (1) | AU2713599A (enExample) |
| BR (1) | BR9908726A (enExample) |
| CA (1) | CA2323493A1 (enExample) |
| DE (1) | DE69928100D1 (enExample) |
| HU (1) | HUP0104984A3 (enExample) |
| IL (1) | IL138319A0 (enExample) |
| NO (1) | NO20004527L (enExample) |
| PL (1) | PL342816A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049632A1 (en) | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibitors against the production and release of inflammatory cytokines |
| EA009523B1 (ru) * | 2002-06-05 | 2008-02-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Ингибиторы в отношении активации ар-1 и nfat |
| CA2488342A1 (en) * | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Therapeutic drug for diabetes |
| US7626042B2 (en) | 2002-06-06 | 2009-12-01 | Institute Of Medicinal Molecular Design, Inc. | O-substituted hydroxyaryl derivatives |
| AU2003242103A1 (en) | 2002-06-06 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc | Antiallergic agents |
| EP1753512B1 (en) * | 2004-05-28 | 2008-07-09 | Nycomed GmbH | Tetrahydropyridothiophenes |
| DE602005007220D1 (de) * | 2004-06-04 | 2008-07-10 | Nycomed Gmbh | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs |
| JP2008501768A (ja) * | 2004-06-11 | 2008-01-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の化合物及びテトラヒドロピリドチオフェンの使用 |
| CA2881078C (en) * | 2004-06-24 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| CA2596202A1 (en) * | 2005-02-09 | 2006-08-17 | Altana Pharma Ag | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| JP2008530053A (ja) * | 2005-02-11 | 2008-08-07 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の治療のための抗増殖性剤としてのテトラヒドロピリドチオフェン |
| EP1926737B1 (en) * | 2005-09-15 | 2017-03-15 | F. Hoffmann-La Roche AG | 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| CN104193761B (zh) * | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| CN102382076B (zh) * | 2010-09-03 | 2016-08-17 | 中国医学科学院药物研究所 | 芳酮和芳酰胺类化合物及其制法和药物用途 |
| CN102838625B (zh) * | 2011-06-22 | 2015-04-15 | 中国科学院上海药物研究所 | 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途 |
| US9682967B2 (en) | 2013-01-28 | 2017-06-20 | H. Lundbeck A/S | N-substituted-5-substituted phthalamic acids as sortilin inhibitors |
| CN104788424A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途 |
| CN104725306A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104725308A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104788425A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途 |
| CN104829629B (zh) * | 2015-03-26 | 2017-03-15 | 天津药物研究院有限公司 | 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途 |
| BR112019001407A2 (pt) | 2016-07-29 | 2019-07-09 | Sunovion Pharmaceuticals Inc. | compostos e composições e usos dos mesmos |
| SG10202100724UA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| EP3582815A1 (en) | 2017-02-16 | 2019-12-25 | Sunovion Pharmaceuticals Inc. | Methods of treating schizophrenia |
| MX2020000523A (es) | 2017-08-02 | 2020-08-20 | Sunovion Pharmaceuticals Inc | Compuestos de isocromano y usos de los mismos. |
| SG11202007823PA (en) | 2018-02-16 | 2020-09-29 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof |
| JP7703449B2 (ja) | 2019-03-14 | 2025-07-07 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
| US12410191B2 (en) | 2019-05-21 | 2025-09-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Macrolide derivatives, preparation method and application thereof |
| KR20230003503A (ko) | 2020-04-14 | 2023-01-06 | 선오비온 파마슈티컬스 인코포레이티드 | 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민 |
| CN118290333A (zh) * | 2020-04-14 | 2024-07-05 | 普渡研究基金会 | 新型淋巴特异性酪氨酸磷酸酶（lyp）抑制剂 |
-
1999
- 1999-03-11 AT AT99907332T patent/ATE308546T1/de not_active IP Right Cessation
- 1999-03-11 CA CA002323493A patent/CA2323493A1/en not_active Abandoned
- 1999-03-11 AU AU27135/99A patent/AU2713599A/en not_active Abandoned
- 1999-03-11 DE DE69928100T patent/DE69928100D1/de not_active Expired - Lifetime
- 1999-03-11 BR BR9908726-0A patent/BR9908726A/pt not_active IP Right Cessation
- 1999-03-11 EP EP99907332A patent/EP1080095B1/en not_active Expired - Lifetime
- 1999-03-11 PL PL99342816A patent/PL342816A1/xx not_active Application Discontinuation
- 1999-03-11 JP JP2000535645A patent/JP2002506072A/ja not_active Withdrawn
- 1999-03-11 IL IL13831999A patent/IL138319A0/xx unknown
- 1999-03-11 KR KR1020007010093A patent/KR20010041814A/ko not_active Withdrawn
- 1999-03-11 CN CN99806016A patent/CN1300291A/zh active Pending
- 1999-03-11 HU HU0104984A patent/HUP0104984A3/hu unknown
-
2000
- 2000-09-11 NO NO20004527A patent/NO20004527L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0104984A3 (en) | 2003-07-28 |
| KR20010041814A (ko) | 2001-05-25 |
| PL342816A1 (en) | 2001-07-02 |
| DE69928100D1 (de) | 2005-12-08 |
| EP1080095B1 (en) | 2005-11-02 |
| CN1300291A (zh) | 2001-06-20 |
| IL138319A0 (en) | 2001-10-31 |
| EP1080095A1 (en) | 2001-03-07 |
| NO20004527L (no) | 2000-11-07 |
| JP2002506072A (ja) | 2002-02-26 |
| AU2713599A (en) | 1999-09-27 |
| HUP0104984A2 (hu) | 2002-04-29 |
| ATE308546T1 (de) | 2005-11-15 |
| CA2323493A1 (en) | 1999-09-16 |
| NO20004527D0 (no) | 2000-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20004527D0 (no) | Modulatorer for proteintyrosinfosfataser (PTPaser) | |
| BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
| DE69807349T2 (de) | Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren | |
| Wei et al. | Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE2, and MMP-13 expression | |
| BR0212512A (pt) | Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta | |
| BRPI0409447A (pt) | ácidos fenilalcanóicos substituìdos | |
| BR0314577A (pt) | Derivados de triazol como inibidores do fator de crescimento de transformação (tgf) | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BRPI0414488A (pt) | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina | |
| Ciobanu et al. | Acute and chronic effects of neurotrophic factors BDNF and GDNF on responses mediated by thermo-sensitive TRP channels in cultured rat dorsal root ganglion neurons | |
| BRPI0510664B8 (pt) | derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios | |
| Olianas et al. | Inhibition of TNF-α-induced neuronal apoptosis by antidepressants acting through the lysophosphatidic acid receptor LPA1 | |
| BR9815596A (pt) | Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase | |
| Farid et al. | Preparation of bee venom-loaded chitosan nanoparticles for treatment of streptozotocin-induced diabetes in male Sprague Dawley rats | |
| Pelc et al. | Incorporation of labelled thymidine in the seminal vesicle of the mouse | |
| Aleem et al. | History and Traditional uses of Tiryaq (Theriac): An important formulation in Unani medicine | |
| Yadav et al. | Therapeutic Action of Capsaicin in the Management of Pain in Osteoarthritis | |
| BRPI0606388A2 (pt) | composto, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto | |
| KR101920152B1 (ko) | 면역증진 효과가 있는 녹용약침 및 이의 조제방법 | |
| Yen et al. | Glycine tomentella Hayata inhibits IL-1β and IL-6 production, inhibits MMP-9 activity, and enhances RAW264. 7 macrophage clearance of apoptotic cells | |
| AU734887B2 (en) | Therapeutic agent and treatment for canine intractable dermatitis | |
| CN108245500A (zh) | 王浆酸在制备治疗腺苷脱氨酶活性升高的疾病药中的用途 | |
| AU2016256704B2 (en) | Pharmaceutical composition increasing cyclic AMP content and availability in vivo, and preparation method thereof | |
| Niswara et al. | Utilizing Water Hyacinth (Eichhornia crassipes) from Srandakan Bantul, Indonesia for ‘Bright Fever Patch’as an Alternative Children’s Fever Therapy | |
| RU2664441C1 (ru) | Способ снижения прооксидантного воздействия ультрафиолетового облучения на организм |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTA A 5O, 6O, 7O E 8O ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |